Brind.
  1. The FDA approved retifanlimab for MCC treatment, following an amended supply and distribution agreement between Incyte and Knight Therapeutics for use in Latin America.

Knight's affiliate submitted an application to ANVISA and secured exclusive distribution rights for Incyte's tafasitamab.

3 reports, 2 independent Updated Aug 27
Gone quiet
Reports
3
Developments
2
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Knight's affiliate submitted an application to ANVISA and secured exclusive distribution rights for Incyte's tafasitamab.

Who's involved

What this event is mainly about
Knight TherapeuticsIncyte

How it developed

Newest first. Tap a step to see who reported it.
  1. Seeking indication approvals in Argentina, Brazil, and Mexico for tafasitamab.1 source
  2. Knight secured exclusive distribution rights for Incyte's tafasitamab in Latin America.1 source

Keep exploring

Part of

The FDA approved retifanlimab for MCC treatment, following an amended supply and distribution agreement between Incyte and Knight Therapeutics for use in Latin America. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • thestarphoenix.com
  • GlobeNewswireKnight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX
1 more outlet ran the same wire story